Bristol-Myers Squibb BMY Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.27B+35.6% | $7.06B+178% | $5.97B+182% | $4.99B+176% | $5.36B+187% | ||
| $3.59B-55.5% | $4.01B-58.2% | $4.91B-51.7% | $6.5B-35.2% | $8.08B-18.1% | ||
| $555M+7.1% | $553M+9.1% | $540M+5.1% | $530M+2.5% | $518M-2.1% | ||
| -$1.03B+11.1% | -$965M+53.8% | -$1.36B+48.0% | -$1.26B+53.2% | -$1.16B+66.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $129M+106% | -$4M+99.7% | $320M— | -$915M— | -$2.24B— | ||
| —— | —— | —— | -$335M-126% | $200M-41.3% | ||
| $13.31B-7.0% | $14.16B-6.8% | $16.62B+10.8% | $15.9B+12.3% | $14.31B+4.3% | ||
| $1.4B+14.2% | $1.31B+5.0% | $1.32B+9.9% | $1.32B+8.6% | $1.22B+0.7% | ||
| $3.93B+113% | $3.94B-81.9% | $2.28B-89.8% | $758M-96.6% | $1.85B-91.3% | ||
| -$3.76B-68.6% | -$4.13B+80.6% | -$2.87B+87.2% | -$1.39B+93.9% | -$2.23B+89.7% | ||
| $5.07B+3.3% | $5.05B+3.7% | $5B+4.1% | $4.95B+3.6% | $4.91B+3.1% | ||
| $11.44B+298% | $10.94B+281% | $872M-82.1% | $3.12B+30.3% | $2.87B+28.3% | ||
| -$10.92B— | -$10.35B— | —— | —— | —— | ||
| $85M+427% | $199M+245% | $47M-46.6% | $124M+559% | -$26M— | ||
| -$1.29B— | -$129M— | —— | —— | —— | ||
| $3.63B+493% | $3.72B-72.2% | $2.36B-83.1% | $1.99B-85.6% | $612M-95.6% | ||
| —— | $351M— | $336M— | $336M— | $0— | ||
| —— | —— | —— | —— | $1.13B+20.0% | ||
| $1.51B-49.3% | $1.1B-62.9% | $2.47B+137% | $2.41B+128% | $2.97B+1,157% | ||
| -$3.31B— | -$441M— | —— | —— | —— | ||
| -$248M— | -$232M— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.07B+11.6% | ||
| $2.11B+255% | $1.98B+76.0% | $1.64B+48.5% | $1.04B-15.0% | $595M-58.2% | ||
| $456M+67.6% | $77M-70.9% | $266M+343% | $217M+4.3% | $272M+72.2% | ||
| -$134M— | -$139M— | -$125M— | —— | —— | ||
| —— | $0— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $11.91B-9.0% | $12.85B-7.9% | $15.3B+10.9% | $14.58B+12.6% | $13.09B+4.6% | ||
| $11.91B-9.0% | $12.85B-7.9% | $15.3B+10.9% | $14.58B+12.6% | $13.09B+4.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bristol-Myers Squibb generate?
- Bristol-Myers Squibb (BMY) generated $13.3B in operating cash flow over the trailing twelve months.
- What is Bristol-Myers Squibb's free cash flow?
- After $1.4B of capital expenditures, Bristol-Myers Squibb's free cash flow was $11.9B over the trailing twelve months, down 9.0% year over year.
- Where does Bristol-Myers Squibb's cash flow data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
